Modality.AI’s Post

Our CSO Dr Michael Welsh is presenting at #BIOEurope in Munich, November 6-8! 📅8 November | 11:00-11:15 | Barcelona room Michael will share data from SiSaf’s pipeline of siRNA-based therapies of rare disease and will explain how RNA-based rare disease therapies can benefit from our Bio-Courier® technology. By stabilizing lipid nanoparticles through a bioabsorbable silicon matrix, #BioCourier technology provides superior stability and transfection efficiency. It also allows to separate carrier manufacture from RNA loading, which minimizes RNA loss and degradation and enables drug preparation at the point of care. 🤝 #Partnering is OPEN, so let’s schedule a partnering meeting: https://bit.ly/3Sm2CY8. 🔗Learn about our Bio-Courier® technology: https://lnkd.in/eSEmb9Uu #BioTech #LifeSciences 

Science for health 2023 will be featuring a round table discussion on how Belgium can become a world biotechnology leader. Focusing on key technologies like ATMP, digital health, and radiotherapy, the panel delves into challenges, opportunities, and best practices. Have we sparked your interest? Register today: https://lnkd.in/e7pK8vCe #sfh2023 #biotech #lifesciences #biologymeetstechnology

Happy Easter from CN Bio! How do you celebrate? Church, chocolate, or spring cleaning - all of the above? It's a perfect time for new beginnings so why not extend this to the lab by renewing and refreshing your scientific workflow too? At CN Bio we are well-equipped to support your adoption of organ-on-chip (OOC) technology, so why not seize the moment and refresh your drug development pipeline. Our user-friendly PhysioMimix® range offers both single and multi-organ platforms - designed to generate reliable, human-relevant in vitro data that can be utilized to enhance your in vivo experimental designs and ultimately, reduce risks in the clinic. Let's break new ground in drug discovery together! Learn more about PhysioMimix OOC and how it can benefit your research. It starts here! 👉 https://bit.ly/4a9ANLt #Easter #NAM #OOC #Innovation #Technology

Credt: ASEA Visit ASEA Sponsor: https://lnkd.in/gEBHNPUh We speak of cell signaling all the time, but what is it exactly? Our patented biotech generates tiny high-energy signaling molecules that get through the cell membrane without help or permission, also known as passive absorption. When they enter your cells, they act as an on-and-off switch turning on signaling within the cell. Once that cell is on, it's signaled to the cells around it, and so on and so forth, creating a cascading effect that contributes to our resilience to stress and overall wellness. These signaling molecules are found in some of our products, including the ASEA Redox Supplement, which helps you respond to stress and get back to the center. It's not magic—it's science. #CellSignaling #CellularHealth #healthybody #magicmolecule

𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐬𝐞 𝐚𝐧 𝐀𝐧𝐭𝐢-𝐂𝐑𝐈𝐒𝐏𝐑 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐓𝐡𝐚𝐭 𝐏𝐮𝐥𝐥𝐬 𝐀𝐩𝐚𝐫𝐭 𝐚 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐱 Researchers in Canada and China report the characterisation of AcrIF25, an anti-CRISPR protein that inhibits the type I-F CRISPR-Cas system by dismantling the fully assembled effector complex. The team, led by Alan Davidson at University of Toronto, reports that AcrIF25 is the first example of a protein that disassembles a large and stable macromolecular complex without any external energy source, and presents it as a paradigm for macromolecular complex inhibitors with potential in biotech applications. The findings were published yesterday in Nature. https://lnkd.in/eAp5uSK6 #crisprmedicinenews #crisprmedicine #crispr #cas9 #geneediting

𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐬𝐞 𝐚𝐧 𝐀𝐧𝐭𝐢-𝐂𝐑𝐈𝐒𝐏𝐑 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐓𝐡𝐚𝐭 𝐏𝐮𝐥𝐥𝐬 𝐀𝐩𝐚𝐫𝐭 𝐚 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐱 Researchers in Canada and China report the characterisation of AcrIF25, an anti-CRISPR protein that inhibits the type I-F CRISPR-Cas system by dismantling the fully assembled effector complex. The team, led by Alan Davidson at University of Toronto, reports that AcrIF25 is the first example of a protein that disassembles a large and stable macromolecular complex without any external energy source, and presents it as a paradigm for macromolecular complex inhibitors with potential in biotech applications. The findings were published yesterday in Nature. https://lnkd.in/eAp5uSK6 #crisprmedicinenews #crisprmedicine #crispr #cas9 #geneediting

Our Chief Scientific Officer dr. Evi Mercken recently presented groundbreaking preclinical data on RJx-01 and its profound impact on treating sarcopenia. Sarcopenia, the age-related loss of muscle strength, poses a growing concern for our aging population. At Rejuvenate Biomed, we are dedicated to pushing the boundaries of scientific research to address this critical health issue. Our CSO's presentation at the ARDD conference highlighted the latest findings from our diligent team of researchers. These findings represent our significant step forward to our first clinical trial and, thus, in our mission to improve the quality of life of millions of people affected by this condition. 💡 Dive deeper into the potential of RJx-01 by reading our recent publication in JCI Insight: https://lnkd.in/gfmviBXW #ARDD #aging #biotech #drugdiscovery #drugdevelopment #sarcopenia

Today's generation of biotech scientists need to take the next step in life sciences innovation. The past few decades have seen a surge of biotech innovation. However, these solutions have only scratched the surface. The life sciences industry has a tough road ahead, but it also promises to change lives. With funding flowing into the industry, we expect to see the amazing innovations taking place today change the face of the life sciences industry. If you didn´t have the change to read it, take a look on our latest CEO’s series article here -> https://lnkd.in/en9tX2uC #Cocoon #BiotechInnovation #LifeSciences #mRNA

🚀 Advancing Human Health with Vector Space Biosciences! 🌌 Vector Space Biosciences uncovers unique biological connections between genes, proteins, and biochemicals, aiming to repurpose existing drugs to enhance human health both on Earth and in space. 🌍🔬✨ Watch the full interview here⬇️⬇️⬇️ https://lnkd.in/eDa7SaKS #vectorspacebiosciences #spaceresearch #Pharma #healthcare #biotech #healthinnovation #innovation #businessnews #business #news #newtothestreet

At Audubon Bioscience, we believe that the advancement of precision medicine in a way that biosamples are properly managed and not wasted, lies in the ability of researchers and biobanks to direct their attentions on custom, built-for-purpose collections. Our capabilities are already being shifted in the direction to accommodate this innovation. Fifty-four percent (54%) of all unique donor cases collected in 2022 were matched, compared to only 25% in 2020. 💉 Advance your research projects with our custom-built-for-purpose biospecimen collections. ✅ Speak to our experts to request a quote here - https://lnkd.in/ea23fErS #biobanking #biospecimenprocurement #cancerresearch